TECHNOLOGY FOCUS - ORGANIC CHEMISTRY - Preferred Components: The acidic medium is 0.1 M aqueous solution of hydrochloric acid, when the oral formulation is placed in acidic medium for 2 hours, the release amount of active ingredient is not greater than 10%, preferably not greater than 5%. The oral formulation is placed in phosphate buffer solution with pH of 6.8 for 45 minutes and release amount becomes greater than or equal to 70%, preferably greater than or equal to 80%. The oral formulation is enteric-coated preparation, preferably tablets, capsule or pellets. The enteric-coated tablets comprise tablet core, isolation layer and enteric coating. The tablet core comprises 17 alpha -ethynyl-androst-5-ene-3 beta , 7 beta , 17 beta -triol. The enteric-coated capsules comprise enteric-coated capsule shell and medicine particles or powders inside the enteric-coated capsule shell. The enteric-coated pellets comprise enteric-coated pellets or enteric-coated pellets filled in capsules, where the enteric-coated pellets include pellets core, pellets isolation layer and pellets enteric coating. The carrier comprises solubilizer, inert substance that provides local alkalic environment, filler, disintegrant, adhesive and lubricant. The isolation layer comprises hydroxypropyl methylcellulose, polyvinylpyrrolidone, hydroxypropyl cellulose, hydroxymethyl cellulose, methylcellulose, ethylcellulose, polyvinyl alcohol, poly(vinyl acetate), polyethylene glycol and mannitol, preferably hydroxypropyl methylcellulose and/or polyvinylpyrrolidone. The enteric coating comprises copolymer of methacrylic acid and methyl methacrylate, cellulose acetate phthalate, hydroxypropyl methylcellulose acetate succinate, hydroxypropyl methylcellulose phthalate, cellulose acetate phthalate, carboxymethyl ethyl cellulose, cellulose acetate trimellitate, phthaloyl poly(vinyl acetate), shellac or their combinations, preferably copolymer of methacrylic acid and methyl methacrylate, cellulose acetate phthalate, and hydroxypropyl methylcellulose acetate succinate. The weight increase of the isolation layer is 1-30%, preferably 2-15%. The weight increase of the enteric coating is 1-30%, preferably 4-15%. The formulation comprises 0-50% inert substance, preferably 0%-40%. The content of 17 alpha -ethynyl-androst-5-ene-3 beta , 7 beta , 17 beta -triol is 0.5-100 mg, preferably 2 mg, 5 mg, 10 mg, 25 mg, 50 mg and 100 mg. The active ingredient comprises crystal form, amorphous substance, dehydrate, solvate, hydrate or enantiomer of 17 alpha -ethynyl-androst-5-ene-3 beta , 7 beta , 17 beta -triol. The solubilizer includes sodium lauryl sulfate, poloxamer, polysorbate, polyoxypropylene alkyl ether, cyclodextrin, polyethylene glycol, polyoxyethylene hydrogenated castor oil or their combination. The filler includes microcrystalline cellulose, lactose, sucrose, starch, pregelatinized starch, mannitol, sugar powder, dextrin or their combinations, where the content of filler is 10-5000%, preferably 50-3000%. The disintegrant is chosen from crosslinked povidone, croscarmellose sodium, sodium starch glycolate, low-substituted hydroxypropyl cellulose, dry starch or their combination. The content of the disintegrant is 0.5-50%, preferably 1-40%. The adhesive is chosen from polyvinylpyrrolidone, hydroxypropyl methylcellulose, hydroxypropyl cellulose, methylcellulose, carboxymethyl cellulose, copovidone, ethylcellulose, polyvinyl alcohol, polyethylene glycol, xanthan gum, alginate, and their combinations, where the concentration of the adhesive is 0.5-50 (%weight/volume). The lubricant is chosen from magnesium stearate, calcium stearate, zinc stearate, stearic acid, glycerol monostearate, micropowder silica gel, talc, hydrated sodium calcium aluminosilicate, polyethylene glycol, hydrogenated plant oil, sodium fumarate, polyoxyethylene monostearate, sucrose monolaurate, sodium dodecyl sulfate, magnesium dodecyl sulfate, magnesium lauryl sulfate, talc or their combinations. The content of lubricant is 0.1-20%, preferably 0.5-5%. The formulation further comprises plasticizer chosen from triethyl citrate, polyethylene glycol, diethyl phthalate, dibutyl, glycerol or castor, preferably triethyl citrate or polyethylene glycol. The drug core is prepared by wet granulating, dry granulating, or mixed powder pressing. ACTIVITY - Antidiabetic; Antiarthritic; Antirheumatic; Antiinflammatory; Antiulcer; Gastrointestinal-Gen.